Quality Sustainability in Pharma: Where Culture Becomes the True Competitive Edge

FDA approves belzutifan plus lenvatinib for advanced ccRCC post-PD-1 failure, with dual-product labeling and a boxed warning for embryo-fetal toxicity.

FDA schedules October 26 hybrid meeting on BsUFA reauthorization for FY2028–2032; public docket closes November 25, 2026.

BD issues Class I correction for convenience kits containing Huons-manufactured sodium chloride ampules, flagging supplier qualification gaps for QA teams.

FDA resolves four-year albuterol shortage; Ritedose's expanded BFS capacity and four-strength portfolio now serve as standing domestic supply infrastructure.